ArticleImmunology2025
Human Alveolar Macrophages Detect SARS-CoV-2 Envelope Protein Through TLR2 and TLR4 and Secrete Cytokines in Response.
Article in Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immune signaling as a determinant of cellular identity and tissue function.Frontiers in immunology · 2026Review
- C-terminus-outward orientation of SARS-CoV-2 envelope proteins on viral capsid enables a novel virus-cell interaction pathway.Frontiers in cellular and infection microbiology · 2026Article
- Advanced nanotherapies for precision treatment of inflammatory lung diseases.Bioactive materials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Alveolar macrophages (AMs) are the most numerous immune cells of the lung and are the resident, sentinel lung immunocytes that summon trafficking immune cells to the compartment. Immune profiling of AMs from COVID-19 patients implicates AMs in the immune circuits that drive pulmonary inflammation in severe COVID-19 infection. However, little is known about human AM responses to SARS-CoV-2 proteins, such as the spike protein and envelope protein. We aimed to understand if human AMs recognize SARS-CoV-2 proteins and how they respond. We found that human AMs do not sense SARS-CoV-2 spike protein but do sense envelope protein via the pattern recognition receptors TLR2 and TLR4, secreting IL-1β, IFNγ, IL-12p70, IL-6, and TNFα in response. AMs from donors over the age of 70 years produced significantly more cytokines than those from younger patients following stimulation with SARS-CoV-2 envelope protein. AMs from current smokers had lower cytokine secretion. This is the first report of human AMs producing cytokines in response to SARS-CoV-2 proteins and the first to correlate those responses with clinical risk factors. These results may partly explain why older adults are at such high risk of severe lung inflammation in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.